News
TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback